The U.S. Food and Drug Administration (FDA) approved a supplemental application for Mounjaro (tirzepatide) on December 19, 2025. This approval, designated as an efficacy supplement, was sponsored by Eli Lilly and Co., indicating an expansion or refinement of the drug's demonstrated effectiveness.
Background
Tirzepatide is known by the brand name Mounjaro. This supplemental approval specifically addresses the efficacy of the drug, suggesting a review of new data supporting its therapeutic benefits.
What this means
A supplemental efficacy approval from the FDA signifies that the agency has evaluated additional clinical data and determined that it supports a new or expanded claim regarding the drug's effectiveness. While the specific details of the new efficacy claim are not provided in the source data, such approvals typically broaden the therapeutic scope of a medication, potentially allowing for its use in a new indication, patient population, or under modified conditions, based on demonstrated efficacy.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) database. The approval for supplemental application NDA 215866 S-39 was posted on December 19, 2025, on accessdata.fda.gov.